{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T11:32:12Z","timestamp":1769167932744,"version":"3.49.0"},"reference-count":27,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2019,3,1]],"date-time":"2019-03-01T00:00:00Z","timestamp":1551398400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,3,1]],"date-time":"2019-03-01T00:00:00Z","timestamp":1551398400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2018,7,16]],"date-time":"2018-07-16T00:00:00Z","timestamp":1531699200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.es","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Anales de Pediatr\u00eda"],"published-print":{"date-parts":[[2019,3]]},"DOI":"10.1016\/j.anpedi.2018.05.022","type":"journal-article","created":{"date-parts":[[2018,8,6]],"date-time":"2018-08-06T09:42:34Z","timestamp":1533548554000},"page":"148-156","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"title":["Efectividad de ivacaftor en vida real en ni\u00f1os con fibrosis qu\u00edstica y mutaci\u00f3n G551D"],"prefix":"10.1016","volume":"90","author":[{"given":"David","family":"Gomez-Pastrana","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chinedu","family":"Nwokoro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mike","family":"McLean","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarah","family":"Brown","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nanna","family":"Christiansen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Caroline S.","family":"Pao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.anpedi.2018.05.022_bib0140","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/j.jcf.2008.03.007","article-title":"The prevalence of cystic fibrosis in the European Union","volume":"7","author":"Farrell","year":"2008","journal-title":"J Cyst Fibros."},{"key":"10.1016\/j.anpedi.2018.05.022_bib0145","unstructured":"Cystic Fibrosis Foundation. Patient Registry 2012 Annual Data Report. USA: Bethesda, MD, 2013."},{"key":"10.1016\/j.anpedi.2018.05.022_bib0150","unstructured":"ECFS Patient Registry Annual Data Report 2008-09, 2012."},{"key":"10.1016\/j.anpedi.2018.05.022_bib0155","doi-asserted-by":"crossref","first-page":"1992","DOI":"10.1056\/NEJMra043184","article-title":"Cystic fibrosis","volume":"352","author":"Rowe","year":"2005","journal-title":"N Engl J Med."},{"key":"10.1016\/j.anpedi.2018.05.022_bib0160","doi-asserted-by":"crossref","first-page":"18825","DOI":"10.1073\/pnas.0904709106","article-title":"Rescue of FQ airway epithelial cell function in vitro by a CFTR potentiator VX-770","volume":"106","author":"Van Goor","year":"2009","journal-title":"Proc Natl Acad Sci USA."},{"key":"10.1016\/j.anpedi.2018.05.022_bib0165","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.jcf.2011.12.005","article-title":"Ivacaftor potentiation of multiple CFTR channels with gating mutations","volume":"11","author":"Yu","year":"2012","journal-title":"J Cystic Fibrosis."},{"key":"10.1016\/j.anpedi.2018.05.022_bib0170","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1056\/NEJMoa1105185","article-title":"A CFTR potentiator in patients with cystic fibrosis and the G551D mutation","volume":"365","author":"Ramsey","year":"2011","journal-title":"New Engl J Med."},{"key":"10.1016\/j.anpedi.2018.05.022_bib0175","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1164\/rccm.201301-0153OC","article-title":"Efficacy and safety of ivacaftor in patients aged 6 to 11 years with cystic fibrosis with a G551D mutation","volume":"187","author":"Davies","year":"2013","journal-title":"Am J Respir Crit Care Med."},{"key":"10.1016\/j.anpedi.2018.05.022_bib0180","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1016\/S2213-2600(14)70218-8","article-title":"Long-term safety and efficacy of ivacaftor in patients with cystic fibrosis who have the Gly551Asp-CFTR mutation: a phase 3, open-label extension study (PERSIST)","volume":"2","author":"McKone","year":"2014","journal-title":"Lancet Respiratory Med."},{"key":"10.1016\/j.anpedi.2018.05.022_bib0185","doi-asserted-by":"crossref","first-page":"S6","DOI":"10.1016\/S1569-1993(14)60019-9","article-title":"The effect of ivacaftor on the rate of lung function decline in FQ patients with a G551D-CFTR mutation","volume":"13","author":"Sawicki","year":"2014","journal-title":"J Cystic Fibrosis."},{"key":"10.1016\/j.anpedi.2018.05.022_bib0190","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1164\/rccm.201404-0703OC","article-title":"Clinical mechanism of the cystic fibrosis transmembrane conductance regulator potentiator ivacaftor in G551D-medicated cystic fibrosis","volume":"190","author":"Rowe","year":"2014","journal-title":"Am J Respir Crit Care Med."},{"key":"10.1016\/j.anpedi.2018.05.022_bib0195","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1093\/cid\/ciu944","article-title":"Pseudomonas aeruginosa in cystic fibrosis patients with G551D-CFTR treated with ivacaftor","volume":"60","author":"Heltshe","year":"2015","journal-title":"Clin Infect Dis."},{"key":"10.1016\/j.anpedi.2018.05.022_bib0200","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1378\/chest.121.1.64","article-title":"Impact of recent pulmonary exacerbations on quality of life in patients with cystic fibrosis","volume":"121","author":"Britto","year":"2002","journal-title":"Chest."},{"key":"10.1016\/j.anpedi.2018.05.022_bib0205","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1164\/rccm.200909-1421OC","article-title":"Failure to recover to baseline pulmonary function after cystic fibrosis pulmonary exacerbation","volume":"182","author":"Sanders","year":"2010","journal-title":"Am J Respir Crit Care Med."},{"key":"10.1016\/j.anpedi.2018.05.022_bib0210","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1378\/chest.13-2397","article-title":"Effects of ivacaftor in patients with cystic fibrosis who carry the G551D mutation and have severe lung disease","volume":"146","author":"Barry","year":"2014","journal-title":"Chest."},{"key":"10.1016\/j.anpedi.2018.05.022_bib0215","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1111\/pedi.12026","article-title":"Insulin secretion improves in cystic fibrosis following ivacaftor correction of CFTR: a small pilot study","volume":"14","author":"Bellin","year":"2013","journal-title":"Pediatr Diabetes."},{"key":"10.1016\/j.anpedi.2018.05.022_bib0220","doi-asserted-by":"crossref","first-page":"2362","DOI":"10.1056\/NEJMc1308349","article-title":"Aquagenic wrinkling of the palms in a patient with cystic fibrosis","volume":"369","author":"Grasemann","year":"2013","journal-title":"N Engl J Med."},{"key":"10.1016\/j.anpedi.2018.05.022_bib0225","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1097\/MPG.0000000000000765","article-title":"Improvement of hepatic steatosis in cystic fibrosis with ivacaftor therapy","volume":"60","author":"Hayes","year":"2015","journal-title":"J Pediatr Gastroenterol Nutr."},{"key":"10.1016\/j.anpedi.2018.05.022_bib0230","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1164\/rccm.201403-0595IM","article-title":"Improvement of sinus disease in cystic fibrosis with ivacaftor therapy","volume":"190","author":"Hayes","year":"2014","journal-title":"Am J Respir Crit Care Med."},{"key":"10.1016\/j.anpedi.2018.05.022_bib0235","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1513\/AnnalsATS.201510-669LE","article-title":"Resolution of intestinal histopathology changes in cystic fibrosis after treatment with ivacaftor","volume":"13","author":"Safe","year":"2016","journal-title":"Ann Am Thorac Soc."},{"key":"10.1016\/j.anpedi.2018.05.022_bib0240","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1016\/j.jcf.2014.09.005","article-title":"Efficacy and safety of ivacaftor in patients with cystic fibrosis and a non-G551D gating mutation","volume":"13","author":"De Boeck","year":"2014","journal-title":"J Cyst Fibros."},{"key":"10.1016\/j.anpedi.2018.05.022_bib0245","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/S2213-2600(15)00246-5","article-title":"Cystic fibrosis ivacaftor, and the Arg117His-CFTR mutation","volume":"3","author":"Accurso","year":"2015","journal-title":"Lancet Respir Med."},{"key":"10.1016\/j.anpedi.2018.05.022_bib0250","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1016\/S2213-2600(15)00201-5","article-title":"Efficacy and safety of ivacaftor in patients with cystic fibrosis who have an Arg117His-CFTR mutation: a double-blind, randomised controlled trial","volume":"3","author":"Moss","year":"2015","journal-title":"Lancet Respir Med."},{"key":"10.1016\/j.anpedi.2018.05.022_bib0255","unstructured":"Altes T, Johnson M, Mugler J, Miller GW, Flors L, Mata J, et al. The effect of ivacaftor, an investigational CFTR potentiator, on hyperpolarized noble gas magnetic resonance imaging in subjects with cystic fibrosis who have the G551D-CFTR mutation. 10.1164\/ajrccm-conference.2012.185.1_MeetingAbstracts.A281410.1164\/ajrccm-conference.2012.185.1_MeetingAbstracts.A2814."},{"key":"10.1016\/j.anpedi.2018.05.022_bib0260","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1007\/s00408-014-9629-y","article-title":"CT imaging of pediatric patients with cystic fibrosis on ivacaftor therapy","volume":"192","author":"Hayes","year":"2014","journal-title":"Lung."},{"key":"10.1016\/j.anpedi.2018.05.022_bib0265","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.jcf.2014.06.011","article-title":"Computed tomography correlates with improvement with ivacaftor in cystic fibrosis patients with G551D mutation","volume":"14","author":"Sheikh","year":"2015","journal-title":"J Cyst Fibros."},{"key":"10.1016\/j.anpedi.2018.05.022_bib0270","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/S2213-2600(15)00545-7","article-title":"Safety, pharmacokinetics, and pharmacodynamics of ivacaftor in patients aged 2-5 years with cystic fibrosis and a CFTR gating mutation (KIWI): an open-label, single-arm study","volume":"4","author":"Davies","year":"2016","journal-title":"Lancet Respir Med."}],"container-title":["Anales de Pediatr\u00eda"],"original-title":[],"language":"es","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1695403318303047?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1695403318303047?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T14:48:32Z","timestamp":1761662912000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1695403318303047"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3]]},"references-count":27,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019,3]]}},"alternative-id":["S1695403318303047"],"URL":"https:\/\/doi.org\/10.1016\/j.anpedi.2018.05.022","relation":{},"ISSN":["1695-4033"],"issn-type":[{"value":"1695-4033","type":"print"}],"subject":[],"published":{"date-parts":[[2019,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efectividad de ivacaftor en vida real en ni\u00f1os con fibrosis qu\u00edstica y mutaci\u00f3n G551D","name":"articletitle","label":"Article Title"},{"value":"Anales de Pediatr\u00eda","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.anpedi.2018.05.022","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Asociaci\u00f3n Espa\u00f1ola de Pediatr\u00eda. Published by Elsevier Espa\u00f1a, S.L.U.","name":"copyright","label":"Copyright"}]}}